| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2013: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Research Abstract |
Chemotherapy-induced peripheral neuropathy (CIPN) is a severe dose-limiting side effect of anticancer drugs because of the lack of effective care. The aim of this study was to discover the biomarkers for early diagnosis and optimal care of CIPN using NGF-differentiated PC12D cells. After treatment with anticancer drugs such as oxaliplatin, paclitaxel and bortezomib, intracellular metabolites were extracted and analyzed by liquid chromatography/mass spectrometry (LC/MS). LC/MS analysis revealed some characteristic changes in the concentration of intracellular metabolites related to treatment with specific types of anticancer drugs.
|
